Cargando…
Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study
This open-label, multinational, pilot study randomized (1:2 ratio) adults with HIV-1 RNA <40 copies per milliliter and nucleos(t)ide-related safety/tolerability issues to switch to ritonavir-boosted atazanavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (n = 37) or the nucleos(t)ide...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JAIDS Journal of Acquired Immune Deficiency Syndromes
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804741/ https://www.ncbi.nlm.nih.gov/pubmed/26605505 http://dx.doi.org/10.1097/QAI.0000000000000904 |
_version_ | 1782423075833249792 |
---|---|
author | van Lunzen, Jan Pozniak, Anton Gatell, Jose M. Antinori, Andrea Klauck, Isabelle Serrano, Oscar Baakili, Adyb Osiyemi, Olayemi Sevinsky, Heather Girard, Pierre-Marie |
author_facet | van Lunzen, Jan Pozniak, Anton Gatell, Jose M. Antinori, Andrea Klauck, Isabelle Serrano, Oscar Baakili, Adyb Osiyemi, Olayemi Sevinsky, Heather Girard, Pierre-Marie |
author_sort | van Lunzen, Jan |
collection | PubMed |
description | This open-label, multinational, pilot study randomized (1:2 ratio) adults with HIV-1 RNA <40 copies per milliliter and nucleos(t)ide-related safety/tolerability issues to switch to ritonavir-boosted atazanavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (n = 37) or the nucleos(t)ide reverse transcriptase inhibitor-sparing regimen of ATV/r plus raltegravir (RAL) (n = 72). At 24 weeks, 35/37 (94.6%) and 58/72 (80.6%) of patients, respectively, maintained virological suppression, the primary endpoint, and 1 (2.7%) and 7 (9.7%), respectively, experienced virological rebound. Corresponding 48-week proportions were 86.5%, 69.4%, 2.7%, and 12.5%, respectively. Adherence was lower and treatment discontinuation was higher with ATV/r+RAL. In conclusion, switching to ATV/r+RAL resulted in a higher virological rebound rate than switching to ATV/r plus tenofovir disoproxil fumarate/emtricitabine. |
format | Online Article Text |
id | pubmed-4804741 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | JAIDS Journal of Acquired Immune Deficiency Syndromes |
record_format | MEDLINE/PubMed |
spelling | pubmed-48047412016-04-11 Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study van Lunzen, Jan Pozniak, Anton Gatell, Jose M. Antinori, Andrea Klauck, Isabelle Serrano, Oscar Baakili, Adyb Osiyemi, Olayemi Sevinsky, Heather Girard, Pierre-Marie J Acquir Immune Defic Syndr Clinical Science This open-label, multinational, pilot study randomized (1:2 ratio) adults with HIV-1 RNA <40 copies per milliliter and nucleos(t)ide-related safety/tolerability issues to switch to ritonavir-boosted atazanavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (n = 37) or the nucleos(t)ide reverse transcriptase inhibitor-sparing regimen of ATV/r plus raltegravir (RAL) (n = 72). At 24 weeks, 35/37 (94.6%) and 58/72 (80.6%) of patients, respectively, maintained virological suppression, the primary endpoint, and 1 (2.7%) and 7 (9.7%), respectively, experienced virological rebound. Corresponding 48-week proportions were 86.5%, 69.4%, 2.7%, and 12.5%, respectively. Adherence was lower and treatment discontinuation was higher with ATV/r+RAL. In conclusion, switching to ATV/r+RAL resulted in a higher virological rebound rate than switching to ATV/r plus tenofovir disoproxil fumarate/emtricitabine. JAIDS Journal of Acquired Immune Deficiency Syndromes 2016-04-15 2016-03-11 /pmc/articles/PMC4804741/ /pubmed/26605505 http://dx.doi.org/10.1097/QAI.0000000000000904 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially. |
spellingShingle | Clinical Science van Lunzen, Jan Pozniak, Anton Gatell, Jose M. Antinori, Andrea Klauck, Isabelle Serrano, Oscar Baakili, Adyb Osiyemi, Olayemi Sevinsky, Heather Girard, Pierre-Marie Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study |
title | Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study |
title_full | Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study |
title_fullStr | Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study |
title_full_unstemmed | Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study |
title_short | Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study |
title_sort | brief report: switch to ritonavir-boosted atazanavir plus raltegravir in virologically suppressed patients with hiv-1 infection: a randomized pilot study |
topic | Clinical Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804741/ https://www.ncbi.nlm.nih.gov/pubmed/26605505 http://dx.doi.org/10.1097/QAI.0000000000000904 |
work_keys_str_mv | AT vanlunzenjan briefreportswitchtoritonavirboostedatazanavirplusraltegravirinvirologicallysuppressedpatientswithhiv1infectionarandomizedpilotstudy AT pozniakanton briefreportswitchtoritonavirboostedatazanavirplusraltegravirinvirologicallysuppressedpatientswithhiv1infectionarandomizedpilotstudy AT gatelljosem briefreportswitchtoritonavirboostedatazanavirplusraltegravirinvirologicallysuppressedpatientswithhiv1infectionarandomizedpilotstudy AT antinoriandrea briefreportswitchtoritonavirboostedatazanavirplusraltegravirinvirologicallysuppressedpatientswithhiv1infectionarandomizedpilotstudy AT klauckisabelle briefreportswitchtoritonavirboostedatazanavirplusraltegravirinvirologicallysuppressedpatientswithhiv1infectionarandomizedpilotstudy AT serranooscar briefreportswitchtoritonavirboostedatazanavirplusraltegravirinvirologicallysuppressedpatientswithhiv1infectionarandomizedpilotstudy AT baakiliadyb briefreportswitchtoritonavirboostedatazanavirplusraltegravirinvirologicallysuppressedpatientswithhiv1infectionarandomizedpilotstudy AT osiyemiolayemi briefreportswitchtoritonavirboostedatazanavirplusraltegravirinvirologicallysuppressedpatientswithhiv1infectionarandomizedpilotstudy AT sevinskyheather briefreportswitchtoritonavirboostedatazanavirplusraltegravirinvirologicallysuppressedpatientswithhiv1infectionarandomizedpilotstudy AT girardpierremarie briefreportswitchtoritonavirboostedatazanavirplusraltegravirinvirologicallysuppressedpatientswithhiv1infectionarandomizedpilotstudy |